# EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT06390059** · PHASE2 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DEVICE:** Tumor Treating Fields
- **DRUG:** Atezolizumab
- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT06390059
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-28
- **Primary completion:** 2025-11-18
- **Final completion:** 2025-11-18
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390059, "EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06390059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*